Condition: Anatomic Stage I Breast Cancer · Anatomic Stage II Breast Cancer · Anatomic Stage III Breast Cancer · Sponsor: Vanderbilt-Ingram Cancer Center
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients would normally receive.
This description comes directly from the study's public registry record.
Vanderbilt-Ingram Services for Timely Access · 800-811-8480 · cip@vumc.org
Always discuss trial participation with your own doctor first.
| Emory University/ Winship Cancer Institute | Atlanta, Georgia, United States | Not Yet Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| Vanderbilt University/Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| University of Texas, Southwestern | Dallas, Texas, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05919108